Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2006; 12(15): 2412-2416
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2412
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2412
n (%) | Mean | Median | |
Sex | |||
Boys | 48 (81.4) | ||
Girls | 11 (18.6) | ||
Age | 6-18 | 10.5 ± 3.24 | 10 |
(yr) | |||
Age of HBV infection | 1-14 | 3.7 ± 3.09 | 3 |
(yr) | |||
Duration of HBV infection | 1-16 | 6.8 ± 3.09 | 6 |
(yr) | |||
Completed previous IFN-α treatment | |||
Yes | 51 (86.4) | ||
No | 8 (13.6) | ||
ALT activity before treatment | 20-664 | 101 ± 96.3 | 76 |
(IU/L) | |||
Inflammation activity score | |||
Grade 1 | 24 (40.7) | ||
Grade 2 | 33 (55.9) | ||
Grade 3 | 2 (3.4) | ||
Grade 4 | 0 | ||
Staging | |||
Stage 0 | 7 (11.9) | ||
Stage 1 | 37 (62.7) | ||
Stage 2 | 12 (20.3) | ||
Stage 3 | 2 (3.4) | ||
Stage 4 | 1 (1.7) | ||
Serum HBV DNA level | 200 - 200 000 | 135 632 ± 81 018 | 200 000 |
(copies/mL) | |||
Lamivudnie dose (mg per kg | 1.3 - 4.1 | 3.0 ± 0.85 | 2.9 |
of body weight) |
Factors that may predict response | ALT normalisation | HBe/anti-HBeseroconversion | Sustained viralresponse |
Sex | χ2(Y)=0.37, P = 0.54 | χ2(Y)=0.13, P = 0.72 | χ2(Y)=0.01, P = 0.76 |
Previous IFN-α treatment | χ2(Y)=0.70, P = 0.76. | χ2(Y)=3.29, P = 0.07 | χ2(Y)=4.42, P = 0.04 |
Children’s age | Z=0.10, P = 0.92 | Z=1.83, P = 0.07 | Z=2.28, P = 0.02 |
Age of HBV infection | Z=0.70, P = 0.49 | Z=-1.49, P = 0.14 | Z=-1.40, P = 0.15 |
Duration of HBV infection | Z=0.13, P = 0.89 | Z=2.99, P = 0.002 | Z=3.33, P < 0.001 |
Inflammation activity score (grading) | Z=0.23, P = 0.82 | Z=1.56, P = 0.12 | Z=1.76, P = 0.08 |
Staging | Z=0.88, P = 0.38 | Z=1.46, P = 0.14 | Z=1.69, P = 0.09 |
ALT activity before treatment | Z=-0.48, P = 0.63 | Z=1.49, P = 0.14 | Z=1.23, P = 0.23 |
Serum HBV DNA level | Z=-0.80, P = 0.07 | Z=-3.29, P = 0.001 | Z=-3.22, P = 0.001 |
Lamivudnie dose per kg of body weight | Z=-0.46, P = 0.64 | Z=-1.75, P = 0.08 | Z=-1.59, P = 0.11 |
- Citation: Liberek A, Szaflarska-Popławska A, Korzon M, Łuczak G, Góra-Gębka M, Łoś-Rycharska E, Bako W, Czerwionka-Szaflarska M. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2412-2416
- URL: https://www.wjgnet.com/1007-9327/full/v12/i15/2412.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i15.2412